• 1. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 2. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 3. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 4. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 5. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Halobenzoic acids and derivatives

Recent Advances in the Application of 5-Bromo-2-fluoro-4-methylbenzoic Acid (CAS: 515135-65-6) in Chemical Biology and Pharmaceutical Research

5-Bromo-2-fluoro-4-methylbenzoic acid (CAS: 515135-65-6) has emerged as a key intermediate in the synthesis of novel bioactive compounds, particularly in the development of pharmaceutical agents targeting various diseases. Recent studies have highlighted its utility in medicinal chemistry, where its unique structural features contribute to enhanced binding affinity and selectivity. This research brief synthesizes the latest findings on the applications, synthetic methodologies, and biological activities associated with this compound.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers utilized 5-bromo-2-fluoro-4-methylbenzoic acid as a precursor for the synthesis of small-molecule inhibitors targeting protein kinases involved in cancer progression. The bromo and fluoro substituents on the aromatic ring were found to significantly improve the compound's interaction with the ATP-binding site of the kinase, leading to potent inhibitory activity. The study reported IC50 values in the nanomolar range, underscoring the compound's potential as a lead structure for anticancer drug development.

Another significant application of 5-bromo-2-fluoro-4-methylbenzoic acid was demonstrated in a recent Nature Communications article, where it served as a building block for the development of positron emission tomography (PET) tracers. The fluorine-18 labeled derivative of this compound exhibited excellent pharmacokinetic properties and high target specificity, making it a promising candidate for imaging studies in neurodegenerative diseases. The research team emphasized the compound's favorable lipophilicity and metabolic stability, which are critical for effective blood-brain barrier penetration.

From a synthetic chemistry perspective, innovative approaches to the preparation of 5-bromo-2-fluoro-4-methylbenzoic acid have been reported. A 2024 Organic Process Research & Development publication detailed a scalable, environmentally friendly synthesis route using continuous flow chemistry. This method achieved an 85% yield with significantly reduced waste generation compared to traditional batch processes, addressing important considerations in green chemistry and industrial production.

The biological activities of derivatives stemming from 5-bromo-2-fluoro-4-methylbenzoic acid have also been extensively investigated. Recent in vitro and in vivo studies have shown that modifications at the carboxylic acid position can yield compounds with diverse pharmacological properties, including anti-inflammatory, antimicrobial, and antiviral activities. Particularly noteworthy is the compound's role in the development of covalent inhibitors, where the bromo substituent serves as an effective leaving group in targeted covalent modification strategies.

Looking forward, the versatility of 5-bromo-2-fluoro-4-methylbenzoic acid positions it as a valuable scaffold for drug discovery. Current research directions include its incorporation into PROTACs (proteolysis targeting chimeras) and other targeted protein degradation platforms, as well as its use in the development of covalent inhibitors for challenging therapeutic targets. The compound's unique combination of halogen substituents continues to inspire innovative applications in chemical biology and pharmaceutical research.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)